Levetiracetam's inhibition of synaptic vesicle glycoprotein 2A and alteration of GABA metabolism and turnover in the striatum may contribute to dyskinesia by influencing striatal dopamine release [15]. The gene discussed is SV2A; the disease is drug-induced dyskinesia.